Calendar

««Mar 2010»»
SMTWTFS
  123456
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 3,590,219
since: 14 May 2006

NIHM study to examine effects of excluding benzodiazepines in Medicare Part D coverage

posted Saturday, 23 June 2007

A new research grant funded by the National Institute of Mental Health (NIMH) will examine the costs and benefits of excluding a commonly prescribed class of anti-anxiety medications — benzodiazepines — from coverage in the new Medicare Part D program. Medicare Part D, the prescription drug coverage plan for people insured by Medicare, went into effect in January 2006. The two-year grant will examine how this large public health initiative is affecting treatment of anxiety disorders in older adults.

The decision to exclude benzodiazepines from Medicare Part D coverage was based in part on clinical studies indicating that even though the medications are an effective treatment for anxiety disorders, older people who take them are at an increased risk for falls and hip fractures, and they may worsen conditions such as emphysema, urinary incontinence and depression. Susan Ettner, PhD, of the University of California, Los Angeles, and colleagues will examine how the exclusion is affecting patient care and the use and costs of health care services, including mental health services.

The researchers will use prescription drug, behavioral and medical claims of Medicare participants enrolled since 2004 to analyze their rates of hospital stays, emergency department visits, doctor's visits, and overall behavioral and medical costs. To assess the short-term effects of the exclusion, the researchers will examine participants who had been taking a benzodiazepine before Medicare Part D went into effect. To assess long-term implications of the exclusion, they will examine participants newly diagnosed with an anxiety-related disorder. These data will be compared with data on individuals whose benzodiazepine coverage was unaffected by the Medicare Part D program.

The researchers seek to understand not only how the change in coverage affects the health of patients, but also whether the change will result in health care savings or additional costs for the Part D program. The results will help to inform the ongoing policy debate about whether Medicare Part D needs to be amended to include coverage for benzodiazepines.

Comment:  
The stated reasons for benzodiazepines being excluded are interesting given the growing realization that when it comes to potentially harmful or unpleasant side-effects, for example the dependency/withdrawal issue, there isn't much between these drugs and antidepressants.

As Anxiety Insights reported recently there is evidence that benzodizepines don't increase the risk of falls and hip fractures. On the other hand, at least one recent study found both tricyclic and SSRI antidepressants significantly increase the risk of falls in the elderly. Another recent study found SSRIs doubled the risk of fractures in those over fifty. Nor is this a new finding. Studies going back to at least 1998 have reached similar conclusions.

tags:  

links: digg this    del.icio.us    technorati    reddit